EFTR down 78% EFFECTOR Therapeutics said Thursday that it won't be moving forward with development of its tomivosertib lung cancer treatment after phase 2 data showed no positive trend.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.